Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-04-10 DOI:10.1007/s11912-024-01521-w

Denise S. Hoogenkamp, Linda J. de Wit–van der Veen, Daphne M. V. Huizing, Margot E. T. Tesselaar, Rachel S. van Leeuwaarde, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Arthur J. A. T. Braat

{"title":"Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors","authors":"Denise S. Hoogenkamp, Linda J. de Wit–van der Veen, Daphne M. V. Huizing, Margot E. T. Tesselaar, Rachel S. van Leeuwaarde, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Arthur J. A. T. Braat","doi":"10.1007/s11912-024-01521-w","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01521-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.

Recent Findings

Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery.

Summary

There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.

Abstract Image

查看原文本刊更多论文

神经内分泌肿瘤患者的放射性核素治疗进展

综述目的深入了解肽受体放射性核素疗法（PRRT）在晚期神经内分泌肿瘤（NET）患者中的作用，并概述将PRRT与局部和全身抗癌治疗相结合的可能策略、化疗（如卡培他滨和替莫唑胺）、靶向治疗（如奥拉帕利、依维莫司和舒尼替尼）和免疫治疗（如尼维单抗和彭博利珠单抗）。此外，PRRT 作为手术前的一种治疗方法也显示出了良好的初步效果。虽然这一领域的研究目前还很有限，但该领域正在迅速发展，许多正在进行的临床试验都旨在满足这一需求并探索新的治疗组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.